GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Fesoterodine (Toviaz)

Local RX List renal extractBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Adult CrCl and pediatric eGFR restrictions differ

The adult table contains a 4 mg row below CrCl 15, while pediatric recommendations differ by weight and do not recommend treatment below eGFR 15 or during dialysis.

Before applying: Match age, weight, renal measure and CYP3A4 interactions; never carry the adult low-clearance row into pediatric NDO.

Also check: Adult CrCl and pediatric eGFR restrictions differ

Rxlist source

GlobalRPh RX List - TOVIAZ

Product / population
Extended-release TOVIAZ; adults with OAB versus children >=6 years with NDO and weight >25 kg.
Renal measure
Adults: Cockcroft-Gault CrCl mL/min. Children: validated pediatric eGFR mL/min/1.73 m2.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

Adults start 4 mg once daily. The renal table allows 8 mg daily at CrCl 30-89 and 4 mg daily at 15-29 or <15; escalation still depends on response and tolerability.

Children >25 through 35 kg: eGFR 30-89, 4 mg daily; below 30 or dialysis, not recommended. Children >35 kg: eGFR 30-89, start 4 mg daily and increase to 8 mg after one week; 15-29, 4 mg daily; below 15 or dialysis, not recommended.

Strong CYP3A4 inhibitors add separate restrictions. Pediatric renal doses were derived using assumed proportional renal effects. Do not apply the adult <15 row to children.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/toviaz-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - Toviaz

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult extended-release dosing only. Pediatric regimens use different weight and renal-function rules.

Renal method: Adult CrCl, mL/min.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - TOVIAZ

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Extended-release TOVIAZ; adults with OAB versus children >=6 years with NDO and weight >25 kg.

Renal method: Adults: Cockcroft-Gault CrCl mL/min. Children: validated pediatric eGFR mL/min/1.73 m2.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

population and metric difference

Adult CrCl and pediatric eGFR restrictions differ

The adult table contains a 4 mg row below CrCl 15, while pediatric recommendations differ by weight and do not recommend treatment below eGFR 15 or during dialysis.

How to use this: Match age, weight, renal measure and CYP3A4 interactions; never carry the adult low-clearance row into pediatric NDO.

GlobalRPh RX List - TOVIAZ

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - ToviazGlobalRPh RX List - TOVIAZ
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/fesoterodine-toviaz/

Usual Dosing (Adults)

Muscarinic antagonist for overactive bladder with urge incontinence, urgency and frequency. Start 4 mg daily; may increase to 8 mg daily based on response/tolerability. Maximum 4 mg/day in severe renal impairment (CrCl <30 mL/min) or with potent CYP3A4 inhibitors such as ketoconazole, itraconazole or clarithromycin. Not recommended in severe hepatic impairment (Child-Pugh C). Swallow whole with liquid, with or without food; do not chew, divide or crush.

4 mg extended-release tablets: light blue, oval, biconvex, film-coated, engraved FS. 8 mg extended-release: blue, oval, biconvex, film-coated, engraved FT.

GRPH-fesoterodine-toviaz-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

Do not exceed 4 mg/day in severe renal impairment (CrCl <30 mL/min).

GRPH-fesoterodine-toviaz-02 · Source section: Renal DosingRenal section finder

Hemodialysis

See the renal dosing section above.

GRPH-fesoterodine-toviaz-03 · Source section: HemodialysisRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Toviaz

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult extended-release dosing only. Pediatric regimens use different weight and renal-function rules.

Renal method: Adult CrCl, mL/min.
Source date: Revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For adults with CrCl below 30 mL/min, doses greater than 4 mg are not recommended. No adjustment is recommended for adult CrCl 30 to 80. Pediatric renal regimens must not be substituted for this adult statement; the source gives separate pediatric weight-specific advice.

RDM33-rxlist-fesoterodine-toviaz-C1 · Source locator: Use in specific populations: renal impairment, adult paragraph.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/toviaz-drug/
Retrieved
2026-09-07
Renal-function method
Adult CrCl, mL/min.
Source date/version
Revision date not established in selected retrieval.
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
e521dd5d73fef94a91e0a8ce993076c6f982ea53f126780b4a39d8862adf6ce2
Rxlist

GlobalRPh RX List - TOVIAZ

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Extended-release TOVIAZ; adults with OAB versus children >=6 years with NDO and weight >25 kg.

Renal method: Adults: Cockcroft-Gault CrCl mL/min. Children: validated pediatric eGFR mL/min/1.73 m2.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Adults start 4 mg once daily. The renal table allows 8 mg daily at CrCl 30-89 and 4 mg daily at 15-29 or <15; escalation still depends on response and tolerability.

Children >25 through 35 kg: eGFR 30-89, 4 mg daily; below 30 or dialysis, not recommended. Children >35 kg: eGFR 30-89, start 4 mg daily and increase to 8 mg after one week; 15-29, 4 mg daily; below 15 or dialysis, not recommended.

Strong CYP3A4 inhibitors add separate restrictions. Pediatric renal doses were derived using assumed proportional renal effects. Do not apply the adult <15 row to children.

RDM41-rxlist-fesoterodine-toviaz-541dc60b8e-C1 · Source locator: Dosage / Use in specific populations: renal impairment

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/toviaz-drug/
Retrieved
2026-09-07
Renal-function method
Adults: Cockcroft-Gault CrCl mL/min. Children: validated pediatric eGFR mL/min/1.73 m2.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
af68141de4bbafe913b56d9091ce6f336e7c7974ae50b799b8f8d85a8f6aba42

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 2 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/fesoterodine-toviaz/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
acfa69d7c1089ab23c64e31a840b5ff37a8571136349b2cbf631eae2a5665e6e
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report